论文部分内容阅读
恶性胸膜渗出(MPE)是胸腔内、外器官恶性肿瘤进展的象征,可通过胸腔穿刺和胸膜活检确诊。目前MPE的治疗可采用反复胸腔穿刺抽液,但易复发。患者呼吸困难,生活质量下降,平均存活期仅6个月,且多次穿刺易造成蛋白丢失及胸膜感染。单纯使用肋间导管引流(ICD)效果欠佳,而多数患者体质虚弱,不能耐受胸腔引流术。故胸膜硬化治疗在减少患者痛苦,提高患者生活质量方面起着重要作用。
Malignant pleural effusion (MPE) is a symbol of malignant tumor progression in the internal and external organs of the chest. It can be diagnosed by thoracentesis and pleural biopsy. At present, the treatment of MPE can be repeated thoracentesis, but it is easy to relapse. The patient had difficulty in breathing and the quality of life was reduced. The average survival period was only 6 months, and multiple punctures caused protein loss and pleural infection. The use of intercostal catheter drainage (ICD) alone is not effective, and most patients are physically weak and cannot tolerate chest drainage. Therefore, pleural sclerotherapy plays an important role in reducing patient suffering and improving the quality of life of patients.